Featuring an interview with Dr Christopher Lieu, including the following topics:
- Historical approach to the adjuvant treatment of localized colorectal cancer (CRC) (0:00)
- Perspectives on earlier-onset colorectal cancer and potential drivers; management of oligometastatic disease (13:16)
- Overview of cell-free DNA (circulating tumor DNA [ctDNA]) and techniques for its measurement (17:03)
- Reliability and prognostic capability of ctDNA as a biomarker for clinical status in patients with localized colorectal cancer (21:10)
- ctDNA assessment and treatment decision-making for patients with Stage II colon cancer (26:38)
- Potential incorporation of ctDNA assays into the management of metastatic colorectal cancer or microsatellite instability-high disease (34:29)
- Available clinical data with ctDNA assessment in localized rectal cancer (38:54)
- Current practice patterns with ctDNA assays for patients with localized colorectal cancer (41:17)
- Case: A woman in her early 40s with resected lower risk Stage III colon cancer requests ctDNA testing (45:47)
- Case: A man in his early 50s with Stage IIIB colon cancer wants to avoid adjuvant chemotherapy (50:39)
- Case: A man in his early 60s with Stage IV colon cancer receives a positive postoperative ctDNA assessment result (53:24)